KR102843240B1 - 신규 psma-결합제 및 이의 용도 - Google Patents

신규 psma-결합제 및 이의 용도

Info

Publication number
KR102843240B1
KR102843240B1 KR1020197038065A KR20197038065A KR102843240B1 KR 102843240 B1 KR102843240 B1 KR 102843240B1 KR 1020197038065 A KR1020197038065 A KR 1020197038065A KR 20197038065 A KR20197038065 A KR 20197038065A KR 102843240 B1 KR102843240 B1 KR 102843240B1
Authority
KR
South Korea
Prior art keywords
psma
alb
delete delete
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197038065A
Other languages
English (en)
Korean (ko)
Other versions
KR20200009091A (ko
Inventor
마르티나 베네소바
크리스티나 뮬러
크리스토프 움브리히트
로저 쉬브리
콘스탄틴 제르노세코브
Original Assignee
이테엠 이소토페 테크놀로기에스 뮈니치 에스이
폴 슈레 앙스띠뛰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/000717 external-priority patent/WO2018233798A1/en
Application filed by 이테엠 이소토페 테크놀로기에스 뮈니치 에스이, 폴 슈레 앙스띠뛰 filed Critical 이테엠 이소토페 테크놀로기에스 뮈니치 에스이
Publication of KR20200009091A publication Critical patent/KR20200009091A/ko
Application granted granted Critical
Publication of KR102843240B1 publication Critical patent/KR102843240B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
    • A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197038065A 2017-05-24 2018-05-24 신규 psma-결합제 및 이의 용도 Active KR102843240B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17000891.6 2017-05-24
EP17000891 2017-05-24
PCT/EP2017/000717 WO2018233798A1 (en) 2017-06-20 2017-06-20 Novel psma-binding agents and uses thereof
EPPCT/EP2017/000717 2017-06-20
PCT/EP2018/063734 WO2018215627A1 (en) 2017-05-24 2018-05-24 Novel psma-binding agents and uses thereof

Publications (2)

Publication Number Publication Date
KR20200009091A KR20200009091A (ko) 2020-01-29
KR102843240B1 true KR102843240B1 (ko) 2025-08-05

Family

ID=62200468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038065A Active KR102843240B1 (ko) 2017-05-24 2018-05-24 신규 psma-결합제 및 이의 용도

Country Status (9)

Country Link
US (1) US11629201B2 (enExample)
EP (1) EP3630204A1 (enExample)
JP (1) JP7340459B2 (enExample)
KR (1) KR102843240B1 (enExample)
CN (1) CN110740757B (enExample)
AU (1) AU2018274184B2 (enExample)
CA (1) CA3060143A1 (enExample)
WO (1) WO2018215627A1 (enExample)
ZA (1) ZA201906832B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US12228480B2 (en) * 2018-11-30 2025-02-18 Revvity Health Sciences, Inc. Biological sample preparation using electric fields
AU2020208492A1 (en) * 2019-01-17 2021-08-12 Case Western Reserve University Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
AU2020296488A1 (en) 2019-06-21 2022-01-20 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
TWI803688B (zh) * 2019-08-26 2023-06-01 行政院原子能委員會核能研究所 一種psma靶向放射診療藥物備製方法
KR102269315B1 (ko) * 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CA3210294A1 (en) * 2021-03-04 2022-09-09 Yoshifumi Maya Compound and radioactive labeling compound
CA3223227A1 (en) * 2021-05-21 2022-11-24 NorthStar Medical Technologies, LLC Urokinase plasminogen activator receptor-targeted radiopharmaceutical
WO2023030509A1 (zh) * 2021-09-03 2023-03-09 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
TW202321204A (zh) * 2021-11-10 2023-06-01 大陸商蘇州瑞核醫藥科技有限公司 靶向前列腺特異性膜抗原的配體化合物及其螯合物與用於前列腺癌診斷和治療的應用
EP4436979A1 (en) * 2021-11-26 2024-10-02 Full-Life Technologies HK Limited Cleavable radioligands for targeting cell surface receptors and uses thereof
AU2023226956A1 (en) * 2022-03-04 2024-09-12 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
KR20250057886A (ko) * 2022-09-07 2025-04-29 쓰리비 파마슈티컬스 게엠베하 전립선 특이적 막 항원 (psma) 리간드 및 그의 용도
WO2024051794A1 (zh) * 2022-09-09 2024-03-14 同宜医药（苏州）有限公司 放射性核素偶联药物及其药物组合物和应用
CN120282804A (zh) * 2022-09-23 2025-07-08 核素迪姆股份公司 高纯度铜放射性药物组合物及其诊断和治疗用途
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
KR20250148672A (ko) * 2023-02-16 2025-10-14 노로이 바이오사이언스 씨오., 엘티디. Psma 표적 방사성 약물 및 그 합성과 응용
WO2024245421A1 (en) * 2023-05-31 2024-12-05 Full-Life Technologies Hk Limited Radioligands for targeting cell surface receptors and uses thereof
AU2024282453A1 (en) * 2023-05-31 2025-12-04 Full-Life Technologies Hk Limited Conjugates and uses thereof
CN120265331A (zh) 2023-07-31 2025-07-04 美国锔责任有限公司 [177Lu]镥-PSMA I&T组合物及其剂量测定、试剂盒、制备方法和使用方法
WO2025088147A1 (en) * 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
WO2025218879A1 (en) 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9687572B2 (en) * 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
ES2732060T3 (es) 2011-08-05 2019-11-20 Molecular Insight Pharm Inc Inhibidores radiomarcados del antígeno de membrana específico de la próstata
HUE068833T2 (hu) 2011-08-17 2025-01-28 Merck & Cie Kmg Albumint megkötõ egységek folát konjugátjai
ES2743433T3 (es) 2013-03-15 2020-02-19 Cancer Targeted Tech Llc Agentes para imágenes de pet dirigidos a psma marcados con 18F
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2018031809A1 (en) 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. J. Choy et al, Theranostics, 7(7), 1928-1939(2017.04.27.) 1부.*
J. Kelly et al, Eur. J. Nucl. Med. Mol. Imaging, 44(4), 647-661(2016.11.15.) 1부.*

Also Published As

Publication number Publication date
KR20200009091A (ko) 2020-01-29
CA3060143A1 (en) 2018-11-29
RU2019141963A (ru) 2021-06-24
JP7340459B2 (ja) 2023-09-07
AU2018274184A1 (en) 2019-11-07
CN110740757B (zh) 2023-04-04
JP2020520902A (ja) 2020-07-16
ZA201906832B (en) 2024-02-28
RU2019141963A3 (enExample) 2021-09-22
CN110740757A (zh) 2020-01-31
AU2018274184B2 (en) 2024-06-13
US20210009715A1 (en) 2021-01-14
US11629201B2 (en) 2023-04-18
WO2018215627A1 (en) 2018-11-29
EP3630204A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
KR102843240B1 (ko) 신규 psma-결합제 및 이의 용도
Benešová et al. Albumin-binding PSMA ligands: optimization of the tissue distribution profile
EP3658194B1 (en) Dual mode radiotracer and -therapeutics
JP7729441B2 (ja) 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、ｉｎ ｖｉｔｒｏ法、及びその化合物
Bailey et al. H2azapa: a versatile acyclic multifunctional chelator for 67Ga, 64Cu, 111In, and 177Lu
JP7109627B2 (ja) 放射性核種錯体を調製するための方法およびキット
JPWO2019065774A1 (ja) 放射性薬剤
US20250170243A1 (en) Stable formulations for radionuclide complexes
Prado et al. Gallium and indium complexes with new hexadentate bis (semicarbazone) and bis (thiosemicarbazone) chelators
WO2018233798A1 (en) Novel psma-binding agents and uses thereof
RU2787105C2 (ru) Новые пса-связывающие агенты и их применение
RU2831681C2 (ru) Новые связывающие опухолевый антиген агенты и их применение
HK40054611A (en) Novel tumor antigen binding agents and uses thereof
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
Trencsényi et al. Comparative preclinical evaluation of 68Ga-NODAGA
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)